Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
09/06/2022 - 08:00 AM
WILMINGTON, Del., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City.
On Monday, September 12, at 1:30 p.m. ET , Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference. The live webcast is available here . The company will also be conducting one-on-one meetings with investors on Tuesday, September 13th . On Wednesday, September 14, at 11:10 a.m. ET , Kris Vaddi, Ph.D. and Dr. Jane Huang, President and Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference New York. The live webcast and replay are available here . The company will conduct one-on-one meetings with investors on Wednesday, September 14th . About Prelude
Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT811, a highly selective, potent, orally bioavailable PRMT5 inhibitor; PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, and PRT3645, a brain penetrant CDK4/6 inhibitor. Additionally, Prelude is progressing a potential first-in-class SMARCA2/BRM protein degrader, with an IND expected in the second half of 2022.
For more information, visit our website and follow us on LinkedIn and Twitter .
Investor Contact: ltrickett@preludetx.com
Media Contact: Helen@ShikCommunications.com
PRLD Rankings
#5192 Ranked by Stock Gains
PRLD Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology
About PRLD
prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.
